About Us

Who We Are

Metabolomic Technologies Inc. is a fast growing company specializing in the development of novel metabolomics-based diagnostics for the healthcare market.

Our lead product, PolypDx™ is the first and only urine-based screening test for the detection and prevention of colorectal cancer. 
Meet our team here

Quote From Our CEO

What an incredible journey it has been for our team. With a clear vision and a focus on innovation, we have introduced novel diagnostic methods to meet the needs of patients and healthcare providers. Metabolomics is an incredible untapped science for early-detection and screening, and we are thrilled to be at the forefront of its application in healthcare.

- Dr. David Chang, CEO

Our Award-winning Flagship Product

Our flagship product, PolypDx™, is the first and only urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer. PolypDx™ provides healthcare professionals with a tool for early screening and detection, enabling the timely removal of polyps before they progress to colorectal cancer, thereby preventing cancer in the first place.

View our accolades

Milestone Timeline

2014

1000-Patient Discovery Trial Completed

2016

Validation Trials Completed

2017

2M CAD Seed Round

2017

PolypDx™ LDT Launched

2018

Canadian Assessment of PolypDx™

2018

2018 Economic Model showing PolypDx™ is cost-effective

2019

US Patent Issued - Completing global IP coverage

2019

Discovery & Validation on additional CRC markers

2019

Closed 3.2M USD Series A Round